Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Anti-tumor necrosis factor (TNF) antibodies are successfully used in the therapy of inflammatory bowel diseases (IBD).However, the molecular mechanism of action of these agents is still a matter of debate.Apart from neutralization of TNF, influence on the intestinal barrier function, induction of apoptosis in mucosal immune cells, formation of regulatory macrophages as well as other immune modulating properties have been discussed as central features.Nevertheless, clinically effective anti-TNF antibodies were shown to differ in their mode-of-action in vivo and in vitro .Furthermore, the anti-TNF agent etanercept is effective in the treatment of rheumatoid arthritis but failed to induce clinical response in Crohn's disease patients, suggesting different contributions of TNF in the pathogenesis of these inflammatory diseases.In the following, we will review different aspects regarding the mechanism of action of anti-TNF agents in general and analyze comparatively different effects of each anti-TNF agent such as TNF neutralization, modulation of the immune system, reverse signaling and induction of apoptosis.We discuss the relevance of the membranebound form of TNF compared to the soluble form for the immunopathogenesis of IBD.Furthermore, we review reports that could lead to personalized medicine approaches regarding treatment with anti-TNF antibodies in chronic intestinal inflammation, by predicting response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10-deficient mice develop chronic enterocolitis
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993) · Cell · doi:10.1016/0092-8674(93)80068-p · Cited by 4,274
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Inflammatory bowel disease: Pathogenesis
Zhang, Y.-Z. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i1.91 · Cited by 1,507
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90192-2 · Cited by 1,325
Sandborn, W. J., van Assche, G., Reinisch, W., Colombel, J., D’Haens, G., Wolf, D. C., Kron, M., Tighe, M. B., Lazar, A., & Thakkar, R. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.032 · Cited by 1,269
HELLER, F., FLORIAN, P., BOJARSKI, C., RICHTER, J., CHRIST, M., HILLENBRAND, B., MANKERTZ, J., GITTER, A., BURGEL, N., & FROMM, M. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.002 · Cited by 1,230
Fuss, I. J., Neurath, M., Boirivant, M., Klein, J. S., de la Motte, C., Strong, S. A., Fiocchi, C., & Strober, W. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.3.1261 · Cited by 1,227
Self-citationSandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J.-F., Reinisch, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.05.048 · Cited by 940
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
REINECKER, H.-C., STEFFEN, M., WITTHOEFT, T., PFLUEGER, I., SCHREIBER, S., MacDERMOTT, R. P., & RAEDLER, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05997.x · Cited by 856
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., & Macdonald, T. T. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90398-0 · Cited by 566
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Crohn’s disease and the NOD2 gene: a role for paneth cells
Lala, S., Ogura, Y., Osborne, C., Hor, S. Y., Bromfield, A., Davies, S., Ogunbiyi, O., Nuñez, G., & Keshav, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00661-9 · Cited by 528
C-Reactive Protein as a Marker for Inflammatory Bowel Disease
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200409000-00026 · Cited by 513
The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor
Grell, M., Wajant, H., Zimmermann, G., & Scheurich, P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.570 · Cited by 478
MACDONALD, T. T., HUTCHINGS, P., CHOY, M.-Y., MURCH, S., & COOKE, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb03334.x · Cited by 478
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
Baert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Arijs, I., Li, K., Toedter, G., Quintens, R., Van Lommel, L., Van Steen, K., Leemans, P., De Hertogh, G., Lemaire, K., Ferrante, M., et al. (2009) · Gut · doi:10.1136/gut.2009.178665 · Cited by 408
Atreya, R., Neumann, H., Neufert, C., Waldner, M. J., Billmeier, U., Zopf, Y., Willma, M., App, C., Münster, T., Kessler, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3462 · Cited by 392
Self-citationMitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., & Harada, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23447 · Cited by 346
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D. K., Salfeld, J., & Sasso, E. H. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.002 · Cited by 317
Zeissig, S., Bojarski, C., Buergel, N., Mankertz, J., Zeitz, M., Fromm, M., & Schulzke, J. D. (2004) · Gut · doi:10.1136/gut.2003.036632 · Cited by 305
Eissner, G., Kolch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298
Reimund, J. M., Wittersheim, C., Dumont, S., Muller, C. D., Baumann, R., Poindron, P., & Duclos, B. (1996) · Journal of Clinical Immunology · doi:10.1007/bf01540912 · Cited by 281
Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S.-I., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 270
Atreya, R., Zimmer, M., Bartsch, B., Waldner, M. J., Atreya, I., Neumann, H., Hildner, K., Hoffman, A., Kiesslich, R., Rink, A. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.032 · Cited by 256
Self-citationShealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., Vafa, O., Gunn, G., Tam, S., Sague, S., et al. (2010) · mAbs · doi:10.4161/mabs.12304 · Cited by 243
TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer
Walczak, H. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01066.x · Cited by 226
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
Shen, C., Assche, G. V., Colpaert, S., Maerten, P., Geboes, K., Rutgeerts, P., & Ceuppens, J. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02309.x · Cited by 223
Vos, A. C. W., Wildenberg, M. E., Duijvestein, M., Verhaar, A. P., van den Brink, G. R., & Hommes, D. W. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.008 · Cited by 218
Hochberg, M. C., Tracy, J. K., Hawkins-Holt, M., & Flores, R. H. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.suppl_2.ii13 · Cited by 207
Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro
Vos, A. C. W., Wildenberg, M. E., Arijs, I., Duijvestein, M., Verhaar, A. P., de Hertogh, G., Vermeire, S., Rutgeerts, P., van den Brink, G. R., & Hommes, D. W. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21818 · Cited by 200
Van den Brande, J. M. H., Koehler, T. C., Zelinkova, Z., Bennink, R. J., te Velde, A. A., ten Cate, F. J. W., van Deventer, S. J. H., Peppelenbosch, M. P., & Hommes, D. W. (2007) · Gut · doi:10.1136/gut.2006.105379 · Cited by 170
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
Taylor, P. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.01.005 · Cited by 169
Jürgens, M., Laubender, R. P., Hartl, F., Weidinger, M., Seiderer, J., Wagner, J., Wetzke, M., Beigel, F., Pfennig, S., Stallhofer, J., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.95 · Cited by 169
Danese, S., Sans, M., Scaldaferri, F., Sgambato, A., Rutella, S., Cittadini, A., Piqué, J. M., Panes, J., Katz, J. A., Gasbarrini, A., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2617 · Cited by 162
Functional Modulation of Crohn’s Disease Myofibroblasts by Anti-Tumor Necrosis Factor Antibodies
Di Sabatino, A., Pender, S. L. F., Jackson, C. L., Prothero, J. D., Gordon, J. N., Picariello, L., Rovedatti, L., Docena, G., Monteleone, G., Rampton, D. S., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.069 · Cited by 158
Leal, R. F., Planell, N., Kajekar, R., Lozano, J. J., Ordás, Í., Dotti, I., Esteller, M., Masamunt, M. C., Parmar, H., Ricart, E., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306518 · Cited by 151
Sashio, H., Tamura, K., Ito, R., Yamamoto, Y., Bamba, H., Kosaka, T., Fukui, S., Sawada, K., Fukuda, Y., Tamura, K., et al. (2002) · Immunogenetics · doi:10.1007/s00251-001-0423-7 · Cited by 150
Pierik, M., Vermeire, S., Steen, K. V., Joossens, S., Claessens, G., Vlietinck, R., & Rutgeerts, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01946.x · Cited by 149
Harashima, S.-I., Horiuchi, T., Hatta, N., Morita, C., Higuchi, M., Sawabe, T., Tsukamoto, H., Tahira, T., Hayashi, K., Fujita, S., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.130 · Cited by 129
Douni, E., & Kollias, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.7.1343 · Cited by 126
Fischer, A., Gluth, M., Pape, U.-F., Wiedenmann, B., Theuring, F., & Baumgart, D. C. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00183.2012 · Cited by 117
Panaccione, R., Colombel, J. F., Sandborn, W. J., D’Haens, G., Zhou, Q., Pollack, P., Thakkar, R. B., & Robinson, A. M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12499 · Cited by 114
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
Olesen, C. M., Coskun, M., Peyrin‐Biroulet, L., & Nielsen, O. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.001 · Cited by 109
Loetscher, H., Schlaeǵer, E.-J., Lahm, H. W., et al. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30479-9 · Cited by 106
Li, Z., Arijs, I., Hertogh, G. D., Vermeire, S., Noman, M., Bullens, D. M. A., Coorevits, L., Sagaert, X., Schuit, F. C., Rutgeerts, P., et al. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21229 · Cited by 103
Casteele, N. V., & Gils, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.374 · Cited by 101
Th17 plasticity and its changes associated with inflammatory bowel disease
Ueno, A., Ghosh, A., Hung, D., Li, J., & Jijon, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12283 · Cited by 90
Higuchi, M., Nagasawa, K., Horiuchi, T., Oike, M., Ito, Y., Yasukawa, M., & Niho, Y. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1996.4291 · Cited by 85
Rutella, S., Fiorino, G., Vetrano, S., Correale, C., Spinelli, A., Pagano, N., Arena, V., Maggiano, N., Repici, A., Malesci, A., et al. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.48 · Cited by 84
Holtmann, M. H., Douni, E., Schütz, M., Zeller, G., Mudter, J., Lehr, H.-A., Gerspach, J., Scheurich, P., Galle, P. R., Kollias, G., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3142::aid-immu3142>3.0.co;2-4 · Cited by 84
Self-citationHlavatý, T., Ferrante, M., Henckaerts, L., Pierik, M. J., Rutgeerts, P. J., & Vermeire, S. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20024 · Cited by 72
Shen, C., Assche, G. V., Rutgeerts, P. J., & Ceuppens, J. L. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000194185.69800.07 · Cited by 71
Perrier, C., Hertogh, G. D., Cremer, J., Vermeire, S., Rutgeerts, P. J., Assche, G. V., Szymkowski, D. E., & Ceuppens, J. L. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.23023 · Cited by 71
Olsen, T., Cui, G., Goll, R., Husebekk, A., & Florholmen, J. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902803507 · Cited by 69
Ueda, N., Tsukamoto, H., Mitoma, H., Ayano, M., Tanaka, A., Ohta, S.-I., Inoue, Y., Arinobu, Y., Niiro, H., Akashi, K., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318280b169 · Cited by 65
Kirchner, S., Boldt, S., Kölch, W., Haffner, S., Kazak, S., Janosch, P., Holler, E., Andreesen, R., & Eißner, G. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0703343 · Cited by 64
Maggi, L., Capone, M., Giudici, F., Santarlasci, V., Querci, V., Liotta, F., Ficari, F., Maggi, E., Tonelli, F., Annunziato, F., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000343467 · Cited by 60
Slevin, S. M., & Egan, L. J. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000533 · Cited by 57
T-cell-directed therapies in inflammatory bowel diseases
Monteleone, G., & Caprioli, F. (2010) · Clinical Science · doi:10.1042/cs20100027 · Cited by 52
Pallai, A., Kiss, B., Vereb, G., Armaka, M., Kollias, G. A., Szekanecz, Z., & Szondy, Z. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501573 · Cited by 45
Corazza, N., Brunner, T., Buri, C., Rihs, S., Imboden, M. A., Seibold, I., & Mueller, C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.036 · Cited by 41
Liu, C., Xia, X., Wu, W. H., Wu, R., Tang, M., Chen, T., Xu, F., Cong, Y., Xu, X., & Liu, Z. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12084 · Cited by 41
Agnholt, J. S., Kelsen, J., Brandsborg, B., Jakobsen, N. O., & Dahlerup, J. F. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/01.meg.0000108344.41221.8b · Cited by 39
Katz, L. H., Kopylov, U., Fudim, E., Yavzori, M., Picard, O., Ungar, B., Eliakim, R., Ben‐Horin, S., & Chowers, Y. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.01.010 · Cited by 37
Wang, Y., Han, G., Chen, Y., Wang, K., Liu, G., Wang, R., He, X., Li, X., Hou, C., Shen, B., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.89 · Cited by 36
Dahlén, R., Strid, H., Lundgren, A., Isaksson, S., Raghavan, S., Magnusson, M. K., Simrén, M., Sjövall, H., & Öhman, L. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12081 · Cited by 32
Derer, S., Till, A., Häsler, R., Sina, C., Grabe, N., Jung, S., Nikolaus, S., Kuehbacher, T., Groetzinger, J., Rose‐John, S., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300384 · Cited by 30
Eder, P., Łykowska‐Szuber, L., Krela‐Kaźmierczak, I., Stawczyk‐Eder, K., Zabel, M., & Linke, K. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.09.006 · Cited by 23
Cited by
Curcumin: an inflammasome silencer
Hasanzadeh, S., Read, M. I., Bland, A. R., Majeed, M., Jamialahmadi, T., & Sahebkar, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104921 · Cited by 327
Maverakis, E., Marzano, A. V., Le, S. T., Callen, J. P., Brüggen, M.-C., Guenova, E., Dissemond, J., Shinkai, K., & Langan, S. M. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0213-x · Cited by 285
Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Ruder, B., Atreya, R., & Becker, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081887 · Cited by 228
“cytotoxicity and complement-dependent cytotoxicity, induction of regulatory T cells, downregulation of mucosal angiogenesis and heightened migration of myofibroblasts [159].”
BackgroundSelf-citationTNF in the liver: targeting a central player in inflammation
Tiegs, G., & Horst, A. K. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00910-2 · Cited by 224
Pott, J., Kabat, A. M., & Maloy, K. J. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.017 · Cited by 205
Metadata
- Authors
- Billmeier, U., Dieterich, W., Neurath, M. F., & Atreya, R.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 22
- Issue
- 42
- Pages
- 9300
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2556315980
- Cited by
- 208
- References
- 77
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.